Key result
Ginsenoside Rg2 pretreatment protects human cardiomyocytes against trastuzumab cytotoxicity by inhibiting apoptosis via Akt/mTOR.
Why the study?
Trastuzumab is associated with severe cardiotoxicity, and whether ginsenoside Rg2 protects human cardiomyocytes against trastuzumab-induced toxicity remained unclear.
Does ginsenoside Rg2 protect human cardiomyocytes against trastuzumab-induced toxicity?
Does ginsenoside Rg2 protect human cardiomyocytes against trastuzumab-induced toxicity?
Ginsenoside Rg2 protects human cardiomyocytes against trastuzumab-induced cardiotoxicity in vitro by activating autophagy, suggesting potential as a therapeutic agent.
Answers are grounded in this paper and cite their sources.
Should not yet alter trastuzumab cardiotoxicity management; leaves open clinical translation of ginsenoside Rg2 cardioprotection.
Trastuzumab (TZM) significantly improves the outcomes of patients with breast cancer; however, it is associated with severe cardiotoxicity. Ginsenoside Rg2 was reported to exert protective effects against myocardial injury and apoptosis in human cardiomyocytes (HCMs). However, whether ginsenoside Rg2 protects HCMs against TZM-induced toxicity remains unclear. The present study investigated the proliferation of HCMs using a Cell Counting Kit-8 assay and Ki67 immunofluorescence staining. Apoptotic cells were detected by Annexin V/propidium iodide staining and flow cytometry. Furthermore, monodansylcadaverine staining was performed to detect cell autophagy. In addition, western blotting was used to detect the expression levels of phosphorylated (p)-Akt, p-mTOR, beclin 1, microtubule associated protein 1 light chain 3α (LC3) and autophagy protein 5 (ATG5) in HCMs. Pretreatment with ginsenoside Rg2 significantly protected HCMs against TZM-induced cytotoxicity by inhibiting apoptosis. Furthermore, pretreatment with ginsenoside Rg2 induced autophagy in HCMs by upregulating the expression levels of p-Akt, p-mTOR, beclin 1, LC3 and ATG5. The results obtained in the present study suggested that ginsenoside Rg2 could protect HCMs against TZM-induced cardiotoxicity by activating autophagy. Therefore, ginsenoside Rg2 may serve as a potential therapeutic agent to prevent TZM-related cardiotoxicity in patients with breast cancer.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied Trastuzumab-induced cardiotoxicity. Ginsenoside Rg2 vs. Trastuzumab alone (100 µg/ml) was evaluated on Cell proliferation and apoptosis (p=<0.01). Pretreatment with ginsenoside Rg2 significantly protected human cardiomyocytes against trastuzumab-induced cytotoxicity by inhibiting apoptosis and inducing autophagy via the Akt/mTOR pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: